Skip to main content
SpringerLink
Log in

HIV-First-Line-Therapie

Erste Fachgesellschaft präferiert ungeboosterte Integrasehemmer

  • PHARMAFORUM
  • Published:
MMW - Fortschritte der Medizin Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  • Pressekonferenz „1 Jahr Dolutegravir — was bedeutet das für die Behandlung der HIV-Infektion?“; München, Februar 2015 (Veranstalter: ViiV Healthcare)

Download references

Author information

Authors and Affiliations

  1. http://www.springermedizin.de

    Matthias Herrmann

Authors
  1. Matthias Herrmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Herrmann, M. Erste Fachgesellschaft präferiert ungeboosterte Integrasehemmer. MMW - Fortschritte der Medizin 157, 80 (2015). https://doi.org/10.1007/s15006-015-3151-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15006-015-3151-x

Search

Navigation